Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711672 | 0.79 | NPSR1 (0.50) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL28982526 | 0.77 | NPSR1 (0.43) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL28982525 | 0.75 | NPSR1 (0.51) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL12076280 | 0.73 | NPSR1 (0.58) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL575575 | 0.72 | ACHE (0.50) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL9614631 | 0.72 | ACHE (0.43) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL28674351 | 0.71 | NPSR1 (0.41) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL9614558 | 0.70 | NPSR1 (0.45) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL575443 | 0.70 | ACHE (0.47) | NPSR1MEN1KMT2AACHEGAA | |
| SCHEMBL3072638 | 0.69 | ACHE (0.43) | NPSR1MEN1KMT2AACHEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582605-B2 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | PRSS1, PPP4C, G6PC1 | NPSR1 1576/4885MEN1 3727/4885KMT2A 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.